All In Biotech

Drug Trial Radar · NCT05084053

A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)

A Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of TAK-771 for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN) in Japanese Subjects

Last checked: Nov 19, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

26

Actual

Start

Jan 19, 2022

Primary completion

Oct 28, 2025

Study completion May 29, 2026

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Oct 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of the study is to check for side effects from TAK-771, and to check how well TAK-771 controls symptoms in Japanese participants with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN) The participants will be treated with TAK-771 for 45 months as a maximum. There will be many clinic visits. The number of visits will depend on the infusion cycles of study drug (every 2, 3, or 4 weeks).

Conditions

  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
  • Multifocal Motor Neuropathy (MMN)

Interventions

  • TAK-771Drug

    Intervention description; Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Epoch 1: Percentage of Participants With CIDP Who Experienced RelapseTime frame: Epoch 1: Baseline up to 6 months
  2. Epoch 1: Change From Baseline in Maximum Grip Strength in the More Affected Hand in Participants With MMNTime frame: Epoch 1: Baseline up to 6 months

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Chiba University Hospital

    Chiba, Japan

  • Kyushu University Hospital

    Fukuoka, Japan

  • Hiroshima University Hospital

    Hiroshima, Japan

  • Kumamoto University Hospital

    Kumamoto, Japan

  • Higashimatsuyama Municipal Hospital

    Saitama, Japan

  • Tokushima University Hospital

    Tokushima, Japan

  • Toyama University Hospital

    Toyama, Japan

  • Aichi Medical University Hospital

    Nagakute, Aichi-ken, Japan

  • Chubu Rosai Hospital

    Nagoya, Aichi-ken, Japan

  • Fujita Health University Hospital

    Toyoake, Aichi-ken, Japan

  • Asahikawa Medical Center

    Asahikawa, Hokkaido, Japan

  • Kansai Rosai Hospital

    Amagasaki, Hyōgo, Japan

  • Hyogo College of Medicine Hospital

    Nishinomiya, Hyōgo, Japan

  • St.Marianna University School of Medicine Hospital

    Kawasaki, Kanagawa, Japan

  • Tohoku Medical and Pharmaceutical University Hospital

    Sendai, Miyagi, Japan

  • Nara Medical University Hospital

    Kashihara, Nara, Japan

  • Shiga University of Medical Science Hospital

    Ōtsu, Shiga, Japan

  • Tokushima National Hospital

    Yoshinogawa, Tokushima, Japan

  • Juntendo University Hospital

    Bunkyo-ku, Tokyo, Japan

  • National Center of Neurology and Psychiatry

    Kodaira, Tokyo, Japan

  • Toho University Omori Medical Center

    Ōta-ku, Tokyo, Japan

  • Tokyo Women's Medical University Hospital

    Shinjuku-ku, Tokyo, Japan

  • Yamaguchi University Hospital

    Ube, Yamaguchi, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.